SOPHiA GENETICS (NASDAQ:SOPH) Insider Philippe Menu Sells 2,700 Shares

SOPHiA GENETICS SA (NASDAQ:SOPH) insider Philippe Menu sold 2,700 shares of the stock in a transaction on Monday, April 6th. The shares were sold at an average price of $4.85, for a total value of $13,095.00. Following the sale, the insider directly owned 283,852 shares in the company, valued at $1,376,682.20. This trade represents a 0.94% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Philippe Menu also recently made the following trade(s):

• On Tuesday, April 7th, Philippe Menu sold 2,400 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $4.87, for a total value of $11,688.00.
• On Thursday, March 19th, Philippe Menu sold 608 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $4.79, for a total value of $2,912.32.

SOPHiA GENETICS Stock Performance

SOPH traded down $0.04 during midday trading on Wednesday, hitting $4.86. 71,758 shares of the company traded hands, compared to its average volume of 188,492. The company’s 50-day moving average is $4.78 and its 200 day moving average is $4.68. The company has a quick ratio of 1.84, a current ratio of 1.96 and a debt-to-equity ratio of 1.01. The firm has a market capitalization of $332.86 million, a PE ratio of -9.53 and a beta of 1.04. SOPHiA GENETICS SA has a 52 week low of $2.58 and a 52 week high of $5.70.

SOPHiA GENETICS (NASDAQ:SOPH) last announced its quarterly earnings results on Tuesday, March 3rd. The company reported ($0.28) EPS for the quarter, missing analysts’ consensus estimates of ($0.20) by ($0.08). SOPHiA GENETICS had a negative return on equity of 50.60% and a negative net margin of 44.22%.The company had revenue of $21.71 million during the quarter, compared to the consensus estimate of $21.20 million. On average, research analysts expect that SOPHiA GENETICS SA will post -0.96 EPS for the current year.

Institutional Trading of SOPHiA GENETICS

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its position in SOPHiA GENETICS by 246.9% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 7,632,871 shares of the company’s stock worth $25,341,000 after acquiring an additional 5,432,871 shares during the period. Federated Hermes Inc. increased its stake in shares of SOPHiA GENETICS by 16.4% in the 2nd quarter. Federated Hermes Inc. now owns 220,000 shares of the company’s stock worth $682,000 after purchasing an additional 31,000 shares in the last quarter. Akre Capital Management LLC raised its holdings in SOPHiA GENETICS by 66.2% in the 2nd quarter. Akre Capital Management LLC now owns 3,719,140 shares of the company’s stock worth $11,529,000 after purchasing an additional 1,481,636 shares during the period. Alta Wealth Advisors LLC purchased a new position in SOPHiA GENETICS during the third quarter valued at $6,708,000. Finally, Savvy Advisors Inc. purchased a new position in SOPHiA GENETICS during the third quarter valued at $48,000. 31.59% of the stock is owned by hedge funds and other institutional investors.

SOPHiA GENETICS News Roundup

Here are the key news stories impacting SOPHiA GENETICS this week:

• Neutral Sentiment: Multiple insiders executed pre-arranged Rule 10b5-1 sales to cover tax obligations — CEO Jurgi Camblong, President Ross Muken, CFO George Cardoza, CTO Abhimanyu Verma, and others. Collectively ~25,000 shares were sold over April 6–7 for roughly $120k at an average price near $4.85–$4.88. Executives still retain large positions, and filings note these were routine plan-driven sales rather than opportunistic exits. CEO Form 4 President Form 4 Insider Form 4

Wall Street Analysts Forecast Growth

Several equities analysts have recently weighed in on the company. Guggenheim increased their price target on SOPHiA GENETICS from $6.00 to $7.00 and gave the company a “buy” rating in a report on Monday, January 26th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of SOPHiA GENETICS in a report on Thursday, January 22nd. Finally, BTIG Research reiterated a “buy” rating and set a $7.00 price objective on shares of SOPHiA GENETICS in a research report on Tuesday, March 3rd. Two research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock has an average rating of “Hold” and an average price target of $7.00.

SOPHiA GENETICS Company Profile

SOPHiA GENETICS SA is a data-driven medicine company founded in 2011 and headquartered in La Tène, Switzerland. The firm develops and operates a cloud-native software platform designed to standardize and analyze complex genomic and radiomic data. Its core offering, the SOPHiA DDM™ platform, leverages artificial intelligence and machine learning algorithms to help healthcare institutions, laboratories and biopharmaceutical partners derive actionable insights from next-generation sequencing and medical imaging datasets.

The SOPHiA DDM™ platform supports a range of clinical applications, including oncology, hereditary diseases and rare genetic disorders.